脓毒症相关凝血病中生物标志物筛选的国际试验设计
脓毒症相关凝血病是从早期代偿性SIC到显性DIC的动态血栓炎症连续体,国际策略分歧源于队列选择、干预时机和结局优先而非生物学差异。在未选择脓毒症人群中大型随机试验常中性,可能因生物学异质性和时间信号稀释。作者提出GLOBAL-SIC/DIC实用国际注册框架,支持生物标志物筛选的干预试验。
要点
- GLOBAL-SIC/DIC框架包括入组时早期分层SIC和显性DIC。
- 采用全球可行的最小核心凝血面板进行统一连续采样。
- 预设分层复合终点使用win ratio分析,优先28天死亡率等。
核心结论
- GLOBAL-SIC/DIC通过结合生物学富集、时间保真性和安全性终点设计,为注册到随机试验转化提供可扩展平台。
研究设计与样本
- 提出GLOBAL-SIC/DIC实用国际注册框架,旨在支持生物标志物筛选的干预试验。
主要发现
- 在未选择脓毒症人群中大型随机试验常中性,可能因生物学异质性和时间信号稀释。
关键数值与推荐
- 框架包括入组时早期分层SIC和显性DIC。
- 采用统一连续采样窗口和全球可行的最小核心凝血面板。
- 预设分层复合终点使用win ratio分析。
- 复合终点层级优先28天死亡率、大出血、临床相关血栓、DIC缓解和器官功能障碍轨迹。
- 扩展机制生物标志物限于中心实验室子研究。
临床怎么用
- 在临床研究中采用GLOBAL-SIC/DIC框架进行生物标志物筛选和终点设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sepsis-associated coagulopathy represents a dynamic thromboinflammatory continuum ranging from early, compensated sepsis-induced coagulopathy (SIC) to overt disseminated intravascular coagulation (DIC). Divergent international strategies reflect differences in cohort selection, timing of intervention, and outcome prioritization rather than fundamental biological disagreement. Large randomized trials conducted in unselected sepsis populations have often yielded neutral results, likely due to biological heterogeneity and temporal signal dilution. We propose GLOBAL-SIC/DIC, a pragmatic international registry designed to support biomarker-selected interventional trials. The framework incorporates: (1) early stratification of SIC and overt DIC at enrollment; (2) harmonized serial sampling windows using a minimal, globally feasible core coagulation panel; and (3) a prespecified hierarchical composite endpoint analyzed using the win ratio. The proposed hierarchy prioritizes 28-day mortality, major bleeding, clinically relevant thrombosis, DIC resolution, and organ dysfunction trajectory. This structure integrates survival, safety, and biologically proximal response measures within a single analytic framework. Expanded mechanistic biomarkers, including markers of endothelial injury, complement activation, and fibrinolytic dysregulation, are confined to central-laboratory substudies to preserve operational feasibility. By combining biological enrichment, temporal fidelity, and safety-aware endpoint design, GLOBAL-SIC/DIC provides a scalable platform for registry-to-randomized trial translation. This methodological convergence aligns early-intervention principles with international safety expectations and supports precision phenotyping in future global research on sepsis-associated coagulopathy.
引用
- Iba T, Helms J, Levy JH, et al. Designing biomarker-selected international trials in sepsis-associated coagulopathy. J Thromb Haemost. 2026. PMID: 42106012. doi:10.1016/j.jtha.2026.04.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。